It’s time to rethink peer review policies—and consider an “Earth Shot Program”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login